Exhibit 99.1
Vaccinex, Inc. Announces Reverse Stock Split
ROCHESTER, N.Y., February 15, 2024 (GLOBE NEWSWIRE) Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering
a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock
split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Companys common stock will trade on a split-adjusted basis.
At the Companys Special Meeting of Stockholders held on February 8, 2024, the Companys stockholders approved a proposal to authorize a
reverse stock split of the Companys common stock, at a ratio of 1-for-4, 1-for-6, 1-for-8, 1-for-10,
1-for-12, and 1-for-14, as to be determined by the Companys Board of Directors. The
Board of Directors approved a 1-for-14 reverse split ratio, and on Wednesday, February 14, 2024, the Company filed a Certificate of Amendment to its Amended and
Restated Certificate of Incorporation to effect the reverse stock split effective as of 5:00 p.m. Eastern Time on Monday, February 19, 2024 (the Effective Time).
The Companys Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price
requirement of The Nasdaq Capital Market. The Company has until March 4, 2024 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the Companys common stock must be at least $1.00 per
share for a minimum of 10 consecutive business days by March 4, 2024.
The Companys shares of common stock will continue to trade on The Nasdaq
Capital Market under the symbol VCNX. The new CUSIP number for the Companys common stock post-reverse stock split is 918640301.
As a
result of the reverse stock split, every fourteen shares of the Companys common stock will automatically be combined into one share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any
stockholders percentage ownership interest in the Companys equity, except to the extent that the reverse stock split results in any of our stockholders receiving whole shares in lieu of fractional shares, as discussed below. Any fraction
of a share of common stock that would be created as a result of the reverse stock split will be rounded up to the next whole share. There will not be a reduction in the total number of authorized shares of common stock.
As of the Effective Time, the number of shares of common stock available for issuance under the Companys equity incentive plans and issuable pursuant to
equity awards immediately prior to the reverse stock split will be proportionately adjusted by the reverse stock split. The exercise prices of the Companys outstanding options will be adjusted in accordance with their respective terms.